Glial tümörlerde microrna-221 ekspresyon seviyelerinin analizi

MicroRNAs (miRNAs) consist of 18–25 nucleotides which a group of endogenous regulatory Ribonucleic Acid (RNA) partipicates as an epigentic mechanism that regulate gene expression by using RNA interference (RNAi) metabolism. miRNAs are found in relationship with pathological processes and begun to be used as biomarker in some diseases. Glial tumors are consisiting 80% of primary brain tumors. The aim of our study is to examine miRNA-221 as a biomarker candidate to define prognosis and/or classification for glial tumors. The hospital-based prospective case-control study consisted of 39 patients with glial tumor surgery and a 40 healthy individuals as control group. The peripheral blood samples were drawn from patients and control group after getting their "informed consent" were collected into EDTA-tubes. miRNA221 expression is evaluated from all blood samples. Of the 39 patients we evaluated, 23 were male (59%) and 16 were female (41%). As for the control group which consist of 40 healty individuals, 25 were male (62,5%) and 15 were female (37,5%). The levels of miRNA221 expression were determined by comparing the ΔCT values of miRNAs and the internal control. When the expression levels of miRNA221was compared according to the ΔCT factor, it was determined that the mean expression value of the patient group was 2,98 ± 2,11 while control group had 0,82 ± 2,27, there was statistically significant difference between the groups (p<0.0001). The expression levels of both miRNA221 was found to be significantly increased in the patient group than the control group. In conclusion, we found that miRNA221 expression could be a biomarker for glial tumors. But further researches must be made to make clear for its sensitivity and specifity to use for prognosis of glial tumors.